Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.

Li, Liangqing; Zhang, Shengwei; Xie, Diya; Chen, Hui; Zheng, Xuelan; Pan, Dun

Li, Liangqing; Zhang, Shengwei; Xie, Diya; Chen, Hui; Zheng, Xuelan; Pan, Dun.

Afiliación

Li L; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.
Zhang S; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.
Xie D; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.
Chen H; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.
Zheng X; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.
Pan D; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China, pandun0220@fjmu.edu.cn.

Onco Targets Ther ; 11: 6111-6118, 2018.

Article en En | MEDLINE | ID: mdl-30275715

Palabras clave

NVP-BEZ235; P13K; chemotherapy; fluorouracil; gastric cancer; mTOR

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Onco Targets Ther Año: 2018 Tipo del documento: Article